Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients

The CLEAR Outcomes trial establishes this new drug as an important addition to available nonstatin LDL-lowering therapies, experts say.
Medscape Medical News

source https://www.medscape.com/viewarticle/989100?src=rss